MCS in the Treatment of Lower Urinary Tract Symptoms

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia

In brief

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Key facts

Study ID

NCT01002417

Run by

Health Ever Bio-Tech Co., Ltd.

People needed

274

Starts

2010-07-01

Expected to finish

2014-02-01

Last updated by the study team

2015-03-03

Who can join

Age: 40 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age ≧ 40 years old
• Not being treated for BPH or LUTS
• PSA ≦ 4 ng/ml and no pathologically-proven prostate cancer
• I-PSS ≥ 10
• No known malignancy
• AST/ALT ≦ 3X UNL
• Creatinine ≦ 3X UNL
• Subjects who sign the informed consent form

You may not qualify if…

• Subjects' LUTS are not BPH-related
• Have been treated with pelvis irradiation or pelvic surgery
• Plan to undergo any invasive procedures within the study period
• Active infection or inflammation
• Considered ineligible by the investigators

Where it is running

• David Geffen School of Medicine at UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.